Quantcast

Biotechnology and Management

The healthcare system costs the United States $2.7 trillion -- 17.5 percent of gross domestic product -- in 2010. More than 40 percent of that cost -- about $1 billion -- comprises pharmaceutical, diagnostics, biotechnology and medical devices.

Through its seven distinguished schools and colleges, Carnegie Mellon University offers complete coverage of the healthcare sector with the Masters in Biotechnology and Management (MSBTM) degree. The MSBTM program focuses on the specific skills associated with our healthcare system's manufacturing segment, broadly referred to as biotechnology management.

CMU’s MSBTM is a partnership among the Tepper School of Business, the Mellon College of Science, and Heinz College's School of Public Policy and Management. Unlike some universities, which host their biotechnology programs and degrees in schools of engineering or science, the CMU MSBTM degree is a truly interdisciplinary program that ensures an equally balanced, yet in-depth emphasis on business and science.

The goal of the program is to train managers who can simultaneously balance regulatory, scientific, and business issues as they provide advice and facilitate communication between the company's chief executive officer and chief scientist.

Features & Benefits:

  • Gain a competitive advantage in an industry expected to grow by 20 percent annually for the foreseeable future.
  • Learn to simultaneously balance regulatory, scientific and business issues.
  • Our MSBTM program is the only known biotechnology management program requiring a science or engineering undergraduate degree.
  • The program features the best CMU has to offer by integrating business management from the Tepper School of Business, policy and regulation from Heinz College, and biotechnology science from Mellon College of Science.